The use of alternative promoters for the cell type-specific expression of a given mRNA/protein is a common cell strategy. NEMO is a scaffold protein required for canonical NF-κB signaling. Transcription of the NEMO gene is primarily controlled by two promoters: one (promoter B) drives NEMO transcription in most cell types and the second (promoter A) is largely responsible for NEMO transcription in liver cells. Herein, we have used a CRISPR/Cas9-based approach to disrupt a core sequence element of promoter B, and this genetic editing essentially eliminates expression of NEMO mRNA and protein in 293T human kidney cells. By cell subcloning, we have isolated targeted 293T cell lines that express no detectable NEMO protein, have defined genomic alterations at promoter B, and do not support canonical NF-κB signaling in response to treatment with tumor necrosis factor (TNF). Nevertheless, non-canonical NF-κB signaling is intact in these NEMO-deficient cells. Expression of ectopic NEMO in the edited cells restores downstream NF-κB signaling in response to TNF. Targeting of the promoter B element does not substantially reduce NEMO expression (from promoter A) in the human SNU-423 liver cancer cell line. We have also used homology directed repair (HDR) to fix the promoter B element in a 293T cell clone. Overall, we have created a strategy for selectively eliminating cell type-specific expression from an alternative promoter and have generated 293T cell lines with a functional knockout of NEMO. The implications of these findings for further studies and for therapeutic approaches to target canonical NF-κB signaling are discussed.
INTRODUCTION
Much of the gene diversity in humans is generated by the use of alternative splicing and alternative promoters (Ayoubi & Van De Ven, 1996 : Davulri et al., 2008 . It is estimated that over 50% of human genes have alternative splicing and/or use alternative promoters, and alternative promoter usage has also been coupled to alternative splicing (Modrek & Lee, 2002; Davuluri et al., 2008; Xin et al. 2008 ). In many cases, alternative promoters are used for the tissue-specific or developmentally timed expression of a given gene, and abnormal alternative splicing or promoter usage has been associated with human disease, especially cancer (Davuluri et al. 2008 ; David & Manley, 2010; Zhang & Manley, 2013; Vacik & Rasda, 2017) . For some genes, alternative promoters direct the expression of an identical protein coding region in different cell types or under different conditions by virtue of the promoters being located upstream of distinct 5' nontranslated exons that splice to a common set of downstream coding exons. Methods for assessing the function of tissue-specific alternative promoter usage for individual genes are limited. In this paper, we have used a CRISPR/Cas9-based targeting approach to investigate cell type-specific promoter expression of a key gene (NEMO) in NF-κB signaling.
The mammalian NF-κB transcription factor is involved in the regulation of many cell and organismal processes (Hayden & Ghosh, 2012) . NF-κB itself is tightly regulated by subcellular localization: that is, NF-κB is located in the cytoplasm when inactive, and is induced to translocate to the nucleus when activated by upstream signals. In canonical NF-κB signaling, NF-κB is activated by IKKβ-mediated phosphorylation of the NF-κB inhibitor IκB, which is then degraded to allow NF-κB to enter the nucleus. In non-canonical signaling, cytoplasmic NF-κB p100 is phosphorylated by IKKα, an event that induces proteasome-mediated processing of p100 to p52, which then enters the nucleus to affect gene expression (Sun, 2011) .
NEMO (NF-κB Essential MOdulator) is a protein that serves as a scaffold for IKKβ in canonical NF-κB signaling (Maubach et al., 2017) . In the absence of NEMO, canonical NF-κB signaling cannot be activated (Schmidt-Supprian et al., 2000) . In contrast, activation of non-canonical processing of NF-κB p100 generally does not require NEMO (Sun, 2011) . As such, NEMO is a key regulator for activation of the canonical NF-κB pathway by a variety of upstream signals, and NEMO serves to distinguish activation of canonical and non-canonical NF-κB pathways.
NEMO is also involved in human disease in two prominent ways. First, mutations in the NEMO gene (IKBKG, chromosome X), which often compromise the ability of NEMO to support activation of NF-κB, lead to a variety of developmental and immunodeficiency diseases in humans (Courtois & Gilmore, 2006; Maubach et al., 2017) . Second, NEMO is required for the constitutive and chronic activation of canonical NF-κB signaling that occurs in a variety of cancers and is required for the ability of these cancer cells to proliferate or survive (i.e., avoid apoptosis) (Maier et al., 2013; Maubach et al., 2017; Puar et al., 2018) . Therefore, inhibition of canonical NF-κB signaling can inhibit proliferation or induce apoptosis in a variety of cell-and animal-based cancer models (Puar et al., 2018) . However, enthusiasm for NF-κB-directed inhibition for cancer therapy was greatly dampened by the finding that systemic and genetic inhibition of canonical NF-κB in animal models leads to liver toxicity and often cancer (Grivennikov et al., 2010; Luedde & Schwabe, 2011) . For example, mice with liver-specific knockouts of NEMO develop liver damage and sometimes cancer (Luedde et al., 2007; Beraza et al., 2009 ).
We had three goals in this research: 1) to demonstrate that CRISPR-based targeting of an alternative promoter can be used to knock down expression of a gene in a cell type-specific manner; 2) to create a NEMO-deficient, highly transfectable human cell line for NEMO mutant analysis; and 3) to establish a proof-of-principle concept for targeting the NF-κB signaling pathway for disease therapy in a way that might circumvent unwanted side effects in the liver.
RESULTS

CRISPR-based targeting of a core promoter sequence in Exon 1B of the
NEMO gene abolishes NEMO protein expression in HEK 293T cells. The human
IKBKG gene (NEMO, herein), encoding the NEMO protein, has four alternative 5' noncoding exons (1D, 1A, 1B, 1C) that direct transcription in a tissue-specific fashion (Fusco et al., 2006) (Fig. 1A) . Exon 1B is the most commonly used first exon in most cell types, and this region has a strong RNApolII, H3K4-me3 and DNAse hypersensitivity peaks in human HEK 293 cells (Fusco et al., 2006) (Fig. 1A) . Moreover, the exon 1B-containing mRNA is part of the major NEMO transcript found on polysomes in human 293T embryonic kidney cells (Floor & Doudna, 2016) . Within exon 1B, we noted a sequence (ACCGCGAAACT) that is just downstream of a major transcription start site (TSS) of the NEMO gene and that is within a consensus sequence which is located near the TSS of many genes (Vo Ngoc et al., 2017a) ( Fig. 1A ). Based on these cumulative observations, we put forth the hypothesis that this sequence is important for efficient transcription of the NEMO gene in 293T cells.
As a first step in testing that hypothesis, we sought to disrupt the predicted exon 1B core promoter element by CRISPR/Cas9 targeting in 293T cells using lentiviral transduction of Cas9 and a gRNA targeting the identified site. After puromycin selection, we performed anti-NEMO Western blotting on extracts from a pool of transduced 293T cells. As shown in Fig. 2A , the levels of NEMO protein were reduced in two independent pools of cells transduced with the lentivirus containing the targeting gRNA as compared to cells transduced with the same vector containing no gRNA. Equal levels of total protein (as judged by β-tubulin Western blotting) were present in both cell lysates, and the FLAG-tagged Cas9 protein was expressed in all transduced cells ( Fig. 2A ).
In an effort to identify a clone of cells with a total disruption of the targeted exon 1B promoter sequence, we picked several clones of puromycin-selected cells transduced with the NEMO-targeting lentivirus. Screening of those cell clones by anti-NEMO Western blotting enabled us to identify a cell clone (clone 1) that expressed less than 5% of the NEMO protein expressed in the parental, wild-type 293T cells ( To characterize the genomic disruptions in clone 1, we used PCR to amplify the region surrounding the gRNA-targeted site and subjected the pooled PCR product to next generation sequencing. We obtained approximately 34,000 sequence reads from the targeted region in clone 1 cells. All relevant sequences from clone 1 cells had disruptions within the predicted gRNA site, and all had disruptions within the consensus core promoter sequence (ACCGCGAAACT). With a cutoff of 0.26% of total reads, we identified 42 genomic disruptions at the targeted site in clone 1 cells (Fig. S1 ). The major genomic disruption (comprising 27.7% of the reads) had a one base pair deletion in the non-variant AAA sequence in the consensus sequence (i.e., from ACCGCGAAACT to ACCGCG_AACT) ( Fig. 2C ). These results make three points: 1) based on the depth of sequencing, there are few, if any, wild-type exon 1B sequences within clone 1; 2) there is genomic heterogeneity at the targeted site within clone 1; and 3) the lack of NEMO protein in clone 1 is likely due to disruption of the targeted sequence, even by as little as a 1-bp deletion.
We next compared the expression of NEMO mRNA in wild-type 293T cells and clone 1 cells. First, we used qPCR to compare the total NEMO mRNA in the wild-type and clone 1 cells, by using primer sets downstream of the targeted upstream region, i.e., in exons 2 and 3 or in exons 6 and 7. As shown in Fig. 2D , the total NEMO mRNA was reduced by at least 50-fold in clone 1 cells. Similarly, using primers in exon 1B and in the proximal first intron to detect unspliced NEMO pre-mRNA, we detected an appropriately sized band in RNA from wild-type 293T cells, but no amplified product when using RNA from clone 1 cells ( Fig. 2E ). The levels of control GAPDH mRNA were similar in both cell types ( Fig. 2E ). Thus, the levels of pre-and mature NEMO mRNA are greatly reduced in clone 1 cells, which have a variety of genomic deletions in a consensus exon 1B core promoter sequence, and these disruptions likely account for the lack of NEMO mRNA and consequently NEMO protein expression in clone 1 cells.
Clone 1 cells are defective for induced activation of NF-κB signaling.
To determine whether the lack of NEMO expression renders clone 1 cells defective for NF-κB signaling, we compared the activation of NF-κB signaling in wild-type and clone 1 cells in response to a variety of agents (TNFα, and DNA-damaging agents camptothecin, VP16, doxorubicin, and gamma irradiation). As shown in Fig. 3A , clone 1 cells did not show increased nuclear NF-κB DNA-binding activity in response to any of these agents, whereas control 293T cells showed robust induction of nuclear NF-κB DNA-binding activity. Moreover, induced phosphorylation of IκBα was not detected in clone 1 cells in response to any of these agents ( Fig. 3A ), but was seen in control 293T cells. As controls, we show that β-tubulin expression and Oct DNA-binding activity are similar in wild-type and clone 1 cells, under all conditions (Fig. 3A ).
To confirm that the lack of responsiveness of clone 1 cells to NF-κB-activating agents was due to the loss of NEMO expression, we transfected clone 1 cells with an expression vector for FLAG-NEMO (which lacks the 5' exon 1B sequences and is therefore not susceptible to gRNA targeting), and then treated the cells with TNFα. As shown in Fig. 3B , re-expression of NEMO in clone 1 cells restored TNFα-induced phosphorylation of IκBα as well as nuclear translocation of NF-κB subunit p65. Taken together, these results indicate that clone 1 cells are specifically defective for stimulusbased activation of canonical NF-κB signaling, and that TNFα-induced activation of NF-κB signaling in clone 1 cells can be restored by re-expression of NEMO.
Reduced genomic heterogeneity in a subclone of clone 1 cells. Because of the
heterogeneity of CRISPR/Cas9-directed genomic deletions at the NEMO core promoter site in clone 1 cells, we sought to isolate a cell clone with a reduced number of genomic disruptions at the targeted site. Therefore, we made cell subclones by plating clone 1 cells at less than one cell per well. Five such cell subclones were then expanded and analyzed.
Like parental clone 1 cells, all subclones expressed no detectable NEMO protein ( Fig.   4A ). Preliminary sequence analysis indicated that clone 1.1 had the least genomic complexity around the targeted site, and so clone 1.1 was the focus of further analysis. As shown in Fig. 4B , analysis of ~16,000 sequence reads of a PCR product covering the genomic disruption of clone 1.1 cells showed that over 99% of the reads contained an 8bp deletion at the targeted site (and about 0.9% of the reads had a 1-bp deletion of an A residue in the triplet of the consensus sequence, i.e., ACCGCG-AACT). A second cell subclone (clone 1.3) had over 80% of its total reads (9,485) showing a 2-bp deletion in the AAA stretch of the consensus sequence (ACCGCG--ACT). As a second method of confirming the genomic editing at the target site in clone 1.1 cells, we used PCR amplification of the targeted site followed by restriction digestion with BsiEI, as there is a BsiEI restriction enzyme site at the wild-type target sequence (see Fig. S2 ) that would be destroyed by the 8-bp deletion in clone 1.1 genomic DNA. As predicted, the PCR product amplified from control 293T cell genomic DNA was digested by BsiEI, but the PCR product from clone 1.1 cell genomic DNA was not digested by BsiEI (Fig. 4C ).
To characterize further the 1.1 and 1.3 cell subclones, we first assessed whether IκBα was phosphorylated in these cells in response to TNFα. As shown in Fig. 4D Activation of non-canonical NF-κB signaling, which occurs by IKKα-directed phosphorylation and processing of NF-κB p100, has generally been found to be independent of NEMO (Sun, 2011) . Consistent with these findings, overexpression of NIK, an activator of non-canonical NF-κB signaling, led to equal levels of NF-κB p100 processing to p52 in both wild-type 293T and clone 1.1 cells ( Fig. 4E ). Of note, the FLAG-Cas9 protein is still expressed in clone 1.1 cells, even after subcloning and extensive passaging ( Fig. 4F ).
HDR-mediated repair of the 8-bp deletion in 1.1 cells. To demonstrate that
NEMO lesions can be repaired, we attempted HDR-mediated repair of the 8-bp deletion locus in clone 1.1 cells. To do so, we co-transfected 1.1 cells with an expression vectors for a gRNA-directed against the site that was created by the 8-bp deletion and for a single-stranded repair oligo that also had a mutation (GGG->GAG) which abolished the adjacent PAM site used for the gRNA (see Table S2 ). The PAM site mutation was included so that the original gRNA and Cas9 in these cells could not target the repaired allele and so that we could confirm that the repair had occurred (and was not, for example, due to contamination). PCR amplification and BsiEI digestion of the targeted locus from HDR-transfected 1.1 cells showed that approximately 5-10% of the PCRamplified product was digested with BsiEI (that is, a titration of wild-type DNA, indicated that approximately 5-10% of the PCR product from HDR-transfected 1.1 cells was digested with BsiEI [not shown]). Moreover, next generation sequencing showed that 11.5% of ~40,000 sequence reads had the wild-type sequence in place of the 8-bp deletion and also had the introduced GAG mutation in the adjacent PAM site ( Fig. S3 ). Western blotting showed that expression of glucose-6-phosphate 1-dehydrogenase protein is not altered in clone 1.1 cells as compared to control cells ( Fig. 4G) . Therefore, the 8-bp deletion in clone 1.1 cells is unlikely to have an effect on G6PD transcription, indicating that the 8-bp deletion inactivates the bi-directional promoter only for NEMO expression.
Expression of G6PD
Treatment of 293T cells with the gRNA against the exon 1B core promoter element and dCas9 also reduces NEMO expression. Based on the above experiments, we reasoned that other methods of targeting the exon 1B region might result in reduced NEMO expression. In particular, targeting of genomic regions with dCas9, which has mutations in its catalytic residues required for DNA-cleaving activity, has been shown to block specific gene expression under some conditions (Lawhorn et al., 2014; Fulco et al., 2016) . Therefore, we first created a version of pLenti-CRISPR2.0 in which Cas9 was mutated at residues 10 and 840 (D10G and H840A), which inactivates the DNA cleaving function of Cas9 (Qi et al., 2013) . As above, we then selected 293T cells that had been transduced with the pLenti-CRISPR2.0-dCas9 vector containing the NEMO exon 1B gRNA. We then measured NEMO expression by Western blotting in pools and clones of puromycin-selected cells. As shown in Fig. 5A , NEMO expression was reduced in two of three pLenti-CRISPR2.0-dCas9 cell clones containing the exon 1B gRNA and in a pool of transduced cells, as compared to the uninfected control 293T cells. As a control, no NEMO protein was detected in a lysate from clone 1.1 cells (Fig. 5A) . The extent of NEMO protein knockdown in the pool of CRISPR2.0-dCas9 cells containing the NEMO exon 1B gRNA was similar to that seen in cells with the exon 1B gRNA and wild-type Cas9 (compare Fig. 5A to Fig. 2A ). As a further control, we show that the dCas9 protein was expressed in cell clones d2 and d3. Moreover, no dCas9 protein was expressed in clone d1, likely explaining why there was no reduction in NEMO protein in those cells ( Fig. 5A ). In addition, G6PD protein expression was not affected in clones or pools of cells with reduced NEMO protein from dCas9/gRNA transduction (Fig. 5B ). Finally, we sequenced the gRNA target site in the genomic DNA from clones d2 and d3. As that the exon 1D promoter is the major promoter used for NEMO transcription in liver cells, with approximately 14-fold higher expression of mRNA from exon 1D than exon 1B in both adult human liver tissue and the HepG2 liver cell line. Therefore, we hypothesized that CRISPR-Cas9-based targeting of the exon 1B core promoter sequence would not substantially affect NEMO expression in liver cells. To test this hypothesis, we transduced SNU-423 human liver cells with our pLenti-Crispr2.0 gRNA-containing vector and selected cells with puromycin. As shown in Fig. 6A , a puromycin-resistant clone of SNU-423 cells (clone L1) transduced with the gRNA vector expressed levels of NEMO protein that were essentially the same as the parental SNU-423 cells. As a control, we show that the clone LI cells expressed Cas9 (Fig. 6A ). In addition, BseE1 digestion of the targeted site in the L1 clone ( Fig. 6B ) and DNA sequencing of the targeted locus in exon 1B showed that approximately 96% of the ~41,000 sequence reads were disrupted by genome editing (Fig. 6C ). qPCR showed that clone L1 cells expressed approximately 60-80% of the levels NEMO mRNA as parental SNU-423 cells (Fig. 6D ).
Western blots of four additional Lenti-Crispr2.0 gRNA-containing SNU-423 cell clones showed that they expressed similar amounts of NEMO as compared to control cells (Fig.   S4 ). Overall, these results indicate that targeting of the NEMO exon 1B promoter does not substantially affect usage of the upstream liver-specific NEMO promoter 1D, and thus, does not dramatically reduce NEMO protein expression in a human liver cell line.
DISCUSSION
In this paper, we have shown that CRISPR-based targeting of a core promoter (Fig. 1A) . This sequence is likely to be important for the initiation of transcription due to binding of a basal transcription protein or complex (Vo Ngoc et al., 2017a, 2017b). Consistent with the core sequence in the exon 1B promoter being a binding site for a transcription complex, we also found that targeting of dCas9 to this element blocks NEMO protein expression ( Fig. 5 ). Although the consensus sequence logo for this 11-bp common promoter element is quite variable (Fig. 1A) , it has three invariable A residues. Of note, all 42 of the genomic deletions in our initial 293T cell clone 1 have disruptions in this AAA sequence, including ~28% of the sequence reads that lack only a single A residue. Given that NEMO mRNA levels were reduced by at least 50-fold in clone 1 cells ( Fig. 2D ) and NEMO protein was essentially undetectable ( Fig. 3A) , it is unlikely that there is any substantial NEMO mRNA expression from the ~28% of NEMO alleles that have the 1-bp deletion in the clone 1 population. Moreover, approximately 90% of the edited alleles in clone 1.3 cells had 1 or 2 bp deletions in the AAA sequence ( Fig. 4B ) and expressed no detectable NEMO protein (Fig. 4A) .
The clone 1 cells were established from a cell clone that was generated on the first transduction step, and yet clone 1 cells had a highly diverse set of at least 42 disruptions at the targeted site (Fig. S1 ). We believe that the target site heterogeneity within this "clone" (clone 1) arose from at least two sources: 1) that not all NEMO alleles were targeted in the originally transduced cell and therefore, additional disruptions occurred after the first cell division; and 2) that some early arising targeted alleles underwent further editing after the first targeting event (e.g., a 1-bp deletion could have been further edited to an 8-bp deletion), since these cells stably express the NEMO gRNA and Cas9.
In contrast, the subclone 1.1 cells were isolated some time after passage of the original clone 1 cells, and thus the NEMO alleles (and the 8-bp deletion) in 1.1 cells were likely stabilized in these clonally re-derived cells. In any event, the clone 1.1 cells (derived from the clone 1 cells) represent a nearly homogenous edited cell line that will likely be useful for researchers who seek to investigate NEMO protein function.
One common method to analyze NEMO mutant function is to re-express the NEMO protein in mouse NEMO knockout cells (Schröfelbauer et al., 2012; Cote et al., 2013) . Such experiments have two limitations: 1) human NEMO proteins are being analyzed in mouse cells, and 2) to establish pure, selected populations of NEMO reconstituted cells can take a month or more. The 1.1 cell line, which has a nearly homogenous and defined 8-bp deletion in exon 1B (Fig. 4B) , is likely to be useful for the rapid analysis of NEMO mutants, as occur in human disease or created in the lab. That is, in an experiment that took less than a week, we showed that transient transfection of 1.1 cells with FLAG-NEMO can restore TNFα-induced phosphorylation of IκBα (Fig. 4D ).
Many cancers rely on canonical NF-κB signaling for growth and survival (Paur et al, 2018) . Relevant to our study, a CRISPR-based screen found NEMO to be among the top 7% of targets for restricting the growth of B-lymphoma cells (Reddy et al., 2017) , and lymphoid cells use promoter B for expression of NEMO (Fusco et al., 2006) . Almost all approaches that have sought to target NF-κB function have been directed at NF-κB pathway protein targets (Gilmore & Garbati, 2011) . The limitations of such protein-based approaches is that, without an efficient organ-specific delivery system, one will affect the NF-κB in non-cancer cells. In particular, such NF-κB-direct approaches have often resulted in liver toxicity because targeting of NF-κB signaling, and even disruption of Finally, we have also shown that we can repair a NEMO mutation by HDR. That is, by HDR we provide evidence that we were able to correct the 8-bp promoter deletion in clone 1.1 cells (Fig. S3 ). This result establishes a precedent for repairing the small genomic alterations in NEMO that have been found in human patients (Maubach et al., 2017) .
Overall, we believe the methods, results, and cell lines generated in this paper will be of interest to others studying NEMO function, and can provide novel methods of gene targeting (possibly for therapeutic purposes) and for investigating in vivo effects of alternative promoter usage. Biologos), supplemented with 50 U/ml penicillin, and 50 µg/ml streptomycin) at 37 °C, 5% CO2, in a humidified incubator.
MATERIALS AND METHODS
Cell
Detailed descriptions of all plasmids and primers used in this paper are presented in Tables S1 and S2. Plasmids pcDNA-FLAG, pcDNA-FLAG-NEMO have been described previously (Herscovitch et al., 2008) . pLentiCRISPRv2.0 is from Addgene (plasmid # 52961; Sanjana et al., 2014) . The gRNA sequences targeting the NEMO exon 1B core promoter (quality score = 96; 39 off-target sites; crispr.mit.edu) or a control sequence (labelled C in Fig. 2B ) slightly downstream of the exon 1B site (Table S2) Table S2 ). The PCR product was purified and then sent out for Next-Generation sequencing (MGH CCIB DNA Core). For restriction enzyme analysis of the edited site, DNA was amplified by standard PCR using primers gDNA Fwd and gDNA Rev (Table   S2 ). From a 50 µl reaction, 7 µl was then digested with BsiEI (New England Biolabs) and analyzed by agarose gel electrophoresis followed by staining with ethidium bromide.
HDR-mediated repair of the mutated NEMO allele in clone 1.1 cells. Clone
1.1 cells were seeded at ~60% confluence in 35-mm tissue culture plates approximately 24 h prior to transfection. The next day, cells were co-transfected with 1.8 µg of px330puro-HDR (see Table S1 ), 0.2 µg of an 84-bp single-stranded HDR template (HDR-1.1; Table S2 ), along with Effectine reagents (QIAGEN; see below) in DMEM containing 10% FBS. On the next day, the transfection media was replaced with fresh DMEM/10% FBS. Two days later, cells were passaged into 60-mm plates with 5 ml DMEM/10%FBS. After allowing the cells to grow out, genomic DNA was isolated and target DNA was amplified by standard PCR using primers NEMO gExon 1B Fwd and NEMO gIntron 1 Rev (see Table S2 ). The PCR product was purified and subjected to Next-Generation sequencing (MGH CCIB DNA Core). Table S2 ). were seeded at ~60% density in a 60-mm tissue culture plates one day prior to transecting with the pcDNA-FLAG empty vector or pcDNA-FLAG-NEMO. Transfections were performed using Effectene Transfection Kit (QIAGEN) as follows: 0.2 µg plasmid, and 1.6 µl Enhancer were diluted to a final volume of 32 µl with EC Buffer, and incubated for 5 min at room temperature for DNA condensation. Then, 2 µl Effectene was added, and samples were incubated for 7 min at room temperature to form Effectene-DNA complexes. The final transfection mixture was brought to 1.8 ml with DMEM/10% FBS, added to 60-mm plates containing 3.2 ml of fresh medium, and incubated overnight.
RNA analysis by RT
Upon reaching confluence (2 days), transfected plates were subcultured into new plates at ~60% density, and incubated again until cells reached confluence (2 days). Cells were then stimulated with 20 ng/ml recombinant TNFα (R&D Systems) diluted in PBS containing 0.1% BSA for 10 min in a 37 °C, 5% CO2 in a humidified incubator. Cells were then lysed on ice and processed for Western blotting as described above.
Nuclear extract preparation. To prepare nuclear fractions, cells were resuspended in 400 µl hypotonic buffer (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl), and were incubated on ice for 10 min. Samples were then supplemented with 55 µl NP-40, vortexed for 10 sec, and pelleted at 500 x g for 5 min at 4 °C. The nuclear pellet was washed with the hypotonic buffer, and re-pelleted as above. To lyse the nuclei, the pellet was resuspended in 60 µl high-salt buffer (20 mM HEPES pH 7.9, 1.5 mM MgCl2, 0.2 mM EDTA, 420 mM NaCl, 25% v/v glycerol), vortexed for 30 sec, and samples were then rocked for 1 h at 4 °C. The nuclear extract was clarified by pelleting debris for 30 min at 13,000 rpm at 4 °C.
SUPPLEMENTAL MATERIAL
Two Supplementary Tables and four Supplementary Figures. 
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